Join BJS Academy
BJS Academy>Randomized clinical ...>Chemotherapy with or...
Normal View Dyslexic View

Chemotherapy with or without algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer.

1 February 2022
Randomized clinical trials HPB
Hewitt, DB, Nissen N, Hatoum H, Musher B, Seng J, Coveler AL et al.
Ann Surg 2022; 275: 45-53.

In this study that included 303 patients, the addition of neoadjuvant immunotherapy did not improve progression-free survival (12. versus 13.4 months in controls) or overall survival (14.3 versus 14.9 months, respectively).

Comment: disappointing negative result.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct239
Randomized clinical trials
Randomized clinical trials
HPB
Chemotherapy with or without algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer.
Hewitt, DB, Nissen N, Hatoum H, Musher B, Seng J, Coveler AL et al.Ann Surg 2022; 275: 45-53.
01022022
In this study that included 303 patients, the addition of neoadjuvant immunotherapy did not improve progression-free survival (12. versus 13.4 months in controls) or overall survival (14.3 versus 14.9 months, respectively).
Comment: disappointing negative result.
Published on: 1 February 2022
Article ID: rct239

Related articles

Temporary portocaval shunt provides superior intraoperative hemodynamics and reduces blood loss and duration of surgery in live donor liver transplantation. A randomized controlled trial.

Kumar M, Patil NS, Mohapatra N, Sindwani G, Dhingra U, Yadav A et al.
Ann Surg 2024; 279: 932-944.

16 August 2024

Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial.

Bang JY, Lakhtakia S, Thakkar S, Buxbaum JL, Waxman I, Sutton B et al, on behalf of the United States Pancreatic Disease Study Group.

16 August 2024

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Labori KJ, Bratlie SO, Andersson B, Angelsen J-H, Biorserud C, Bjornsson B et al, for the Nordic Pancreatic Cancer Trial-1 study group.

30 August 2024
Home
  • Normal view
  • Dyslexic view
Info
Copied!